Eastham JA, Carver B, Katz J, Kattan MW. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men. Prostate 2002;50:236-40.Eastham JA, Carver B, Katz J, Kattan MW. Clinical stage T1c prostate cancer: pathologic outcomes following radical ...
prostate specific antigen levels as a criterion for tumor recurrence in a series of 925 consecutive men with clinical stage T1 or T2 prostate cancer. Over... WJ Catalona,DS Smith - 《Journal of Urology》 被引量: 1699发表: 1994年 PSA-detected (clinical stage T1c or B0) prostate cancer. ...
CONCLUSIONS: Impalpable tumors should not be regarded as insignificant or innocuous on the basis of pathological analysis. Disease-free survival in the stage T1c group was similar to that in the clinical stages T1a to T2a group but significantly better than that in the T2b/c group. 展开 ...
Definition: clinical stage T1c, Gleason score ≤ 6, PSA < 10 ng/mL, presence of disease in fewer than 3 biopsy cores, ≤ 50% PC involvement in any core, and PSA density < 0.15 ng/mL/g. Options Level I Recommendations Level II Recommendations Initial therapy Radical pr...
The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and ...
(2009) Editorial Comment on: Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen... AJ Stephenson,JS Jones,AV Hernandez,... 被引量: 0发表: 2009年 Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen ...
Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. We assess whether the Gleason grade changes in men followed expectantly with clinical stage T1c prostate cancer. We studied 70 men with stage T1c prostate ... JI Epstein,PC Walsh,H Ballantine...
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374. doi:10.1001/jama.1994.03510290050036ArticlePubMedGoogle ScholarCrossref 21. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, ...
Fuller’s was one of the initial studies, after which several clinical reports have supported the use of CK-SBRT in low- to intermediate-risk prostate cancer treatment. The present study is an update of our preliminary CK-SBRT experience[17] of 45 low- to intermediate-risk prostate cancer ...
National Prostate Cancer Detection Project, the proportion of locally advanced (clinical state T3) and metastatic (stage T1-4N0-1M1) prostate cancer (... IH Derweesh,PA Kupelian,C Zippe,... - 《Urologic Oncology Seminars & Original Investigations》 被引量: 327发表: 2004年 Increasing national...